GlycoMimetics appoints Scott Koenig to board
Dr. Koenig has been President, CEO and a director of MacroGenics since 2001 and was one of the company’s founders.
Previously, Dr. Koenig was Senior Vice President of Research at MedImmune, participating in the selection and maturation of the company’s product pipeline.
Before that, he worked in the National Institute of Allergy and Infectious Diseases’ Laboratory of Immunoregulation.
In addition to serving as Chair of the Applied Genetic Technologies Corporation, Dr. Koenig also serves as a member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance, and co-chairs the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland.
Previously, Dr. Koenig served as a member of the Scientific Management Review Board at the NIH, and of the Board of Directors of Children’s National Health System, where he was also the Chairman of the Board of the Children’s Research Institute.
Dr. Koenig received his M.D. from the University of Texas Health Science Center in Houston, and his Ph.D. and A.B. from Cornell University. ■
LATEST MOVES FROM Maryland
- Osiris Therapeutics appoints Linda Palczuk as CEO
- Host Hotels & Resorts appoints Mary Hogan Preusse to board
- McCormick & Company appoints Tony Vernon to board
- Intrexon appoints Mark Carnegie-Brown as Oxitec CEO
- Integrace Copper Ridge names Russell L. Mitchell as director
More inside POST